An unusual BRCA mutation distribution in a high risk cancer genetics clinic

Kurian AW (2010) BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications. Curr Opin Obstet Gynecol 22(1):72–78

Hall MJ et al (2009) BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer 115(10):2222–2233

Euhus DM (2011) New insights into the prevention and treatment of familial breast cancer. J Surg Oncol 103(4):294–298

Moran A, O’Hara C, Khan S, Shack L, Woodward E, Maher ER, Lalloo F, Evans DG (2012) Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer 11:235–242. doi: 10.1007/s10689-011-9506-2

Garber JE, Offit K (2005) Hereditary cancer predisposition syndromes. J Clin Oncol 23(2):276–292

Russo A et al (2009) Hereditary ovarian cancer. Crit Rev Oncol Hematol 69(1):28–44

Fisher B et al (1998) Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 90(18):1371–1388

Visvanathan K et al (2009) American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27(19):3235–3258

Lostumbo L, Carbine NE, Wallace J (2010) Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. doi: 10.1002/14651858.CD002748.pub3

Kauff ND, Barakat RR (2007) Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J Clin Oncol 25(20):2921–2927

Bevers TB (2007) The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women. J Natl Compr Canc Netw 5(8):719–724

Goss PE et al (2011) Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364(25):2381–2391

Keshavarzi F, Javadi GR, Zeinali S (2012) BRCA1 and BRCA2 germline mutations in 85 Iranian breast cancer patients. Fam Cancer 11(1):57–67

Malone KE et al (2006) Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res 66(16):8297–8308

Ford D et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet 62(3):676–689

Satagopan JM et al (2002) Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 8(12):3776–3781

Census U Quick Facts. 2012; Available from: http://quickfacts.census.gov/qfd/states/04/04019.html

InfoGroup, o.b.t.A. Survey: Religion 2009. 2009; Available from: http://www.socialexplorer.com/pub/reportdata/docbrowser.aspx?survey=Religion_InfoUSA09&header=True

BRCA1, I.C. The Breast Cancer Information Core Database. 2012; Available from: http://research.nhgri.nih.gov/bic/

Weitzel JN et al (2005) Prevalence of BRCA mutations and founder effect in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev 14(7):1666–1671